MengBloom™ Human Growth Hormone (rhGH) is produced in E. coli inclusion bodies using JHM Biopharma’s proprietary platform technology. Following denaturation, renaturation, and multi-step purification, the product achieves high purity and high biological activity.

Key Features

• Biosimilar development, with head-to-head comparative studies against the reference drug
• Equivalent efficacy and quality to the reference drug (Norditropin®), supported by commercial-scale manufacturing
• Independent intellectual property and patented technology, strengthening competitive advantage
• Cost-efficient production under high-standard GMP compliance, ensuring consistent quality and safety

Indications

• For the treatment of growth disorders in children caused by insufficient secretion of growth hormone.

Clinical Trial Results

• Clinical trials demonstrated that MengBloom™ achieved statistically significant superiority at primary efficacy endpoints, confirming both its therapeutic efficacy and favorable safety profile